Inflammation and Steatosis: the Role of Alpha-defensin

Overview

The aim of this study is to examine the correlation between the severity of non-alcoholic steatohepatitis/non alcoholic fatty liver disease (NASH/NAFLD) in naïve and hepatitis C (HCV) positive patients and the amplitude of alpha-defensin immunohistochemical staining in liver biopsy.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: July 2018

Interventions

  • Diagnostic Test: Immunohistochemical staining
    • Pathological liver slides to be immunohistochemically stained for alpha-defensin

Clinical Trial Outcome Measures

Primary Measures

  • Amplitude of immunohistochemical stain
    • Time Frame: Six months
    • The amplitude of each slide will be graded from 1-4

Participating in This Clinical Trial

Inclusion Criteria

  • Fatty liver disease patients with liver biopsy Exclusion Criteria:

  • None

Gender Eligibility: All

Minimum Age: 15 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hillel Yaffe Medical Center
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Rami Abu Fanne, MD, Study Director, Hillel Yaffe Medical Center
  • Overall Contact(s)
    • Rami Abu Fanne, MD, 972-50-3573694, ramia@hadassah.org.il

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.